{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:10:33Z","timestamp":1789708233168,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This prospective real\u2010world study aimed to assess the efficacy and safety of eribulin in the clinical practice against advanced breast cancer (ABC) in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>In this study, eligible patients with inoperable locally advanced or metastatic breast cancer who had experienced prior neo\u2212\/adjuvant or failed the palliative treatment with anthracycline\/taxanes were included. Eribulin (1.4\u2009mg\/m<jats:sup>2<\/jats:sup>) was infused intravenously on Day 1 and Day 8 every 3\u2009weeks until disease progression or intolerable toxicity occurred. The progression\u2010free survival (PFS), overall response rate (ORR), disease control rate (DCR), and safety of the treatment were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and thirty\u2010four patients were enrolled. The median PFS (mPFS) was 4.3\u2009months (95% CI: 0.3\u201315.4). The ORR and DCR was 32.1% and 79.1%, respectively. The mPFS of patients who received eribulin as first\u2010 or second\u2010line treatment was significantly better than those who received eribulin as \u22653\u2010line treatment (6.9\u2009months [95% CI: 3.2\u20138.8] vs. 4.0\u2009months [95% CI: 3.4\u20134.6], <jats:italic>p<\/jats:italic>\u2009=\u20090.006). The mPFS of patients with triple\u2010negative, HER2\u2010positive, and HER2(\u2212)\/HR(+) was 3.4 (95% CI: 2.7\u20134.1), 6.2 (95% CI: 2.3\u201310.1) and 5.0\u2009months (95% CI: 4.1\u20135.9), respectively. HER2(+) patients had significantly longer PFS than TNBC patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.022). Patients received combination therapy had a significantly longer mPFS than those who received eribulin monotherapy (5.0\u2009months [95% CI 3.6\u20136.3] vs. 4.0\u2009months [95% CI: 3.3\u20134.7] [<jats:italic>p<\/jats:italic>\u2009=\u20090.016]). Multivariate analysis revealed that MBC patients with a molecular typing of non\u2010TNBC receiving eribulin as \u22642\u2010line therapy and combination therapy had a low risk of disease progression. Neutropenia (33.58%), leukopenia (11.94%), and thrombocytopenia (4.48%) were the most common treatment\u2010related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Eribulin demonstrated effective clinical activity and a favorable tolerability profile in Chinese patients with ABC in the real\u2010world. The efficacy and safety profile were consistent with those reported in previous randomized phase 3 trials.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.7295","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T10:35:10Z","timestamp":1716546910000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline\/taxanes"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-8157","authenticated-orcid":false,"given":"Lan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, West China Hospital Sichuan University  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Head and Neck Cancer Department, West China Hospital  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-9344","authenticated-orcid":false,"given":"Ting","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Head and Neck Cancer Department, West China Hospital  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinglun","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Head and Neck Cancer Department, West China Hospital  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Head and Neck Cancer Department, West China Hospital  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Head and Neck Cancer Department, West China Hospital  Chengdu Sichuan Province People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.776"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2012.03.003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0030"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-20301-6_8"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1210-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040916"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky062"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi901810u"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12488"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13392"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0080-4"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4726"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30569-0"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00991-6"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04341-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3524"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0367-x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3846-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.973063"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32402"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.06.015"},{"key":"e_1_2_10_29_1","first-page":"100019","volume-title":"Clinical and Pharmacogenetic Results on Behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","author":"Pellegrino B.","year":"2021"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1705"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526140"},{"issue":"5","key":"e_1_2_10_32_1","first-page":"1876","article-title":"Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study","volume":"24","author":"Oruc Z","year":"2019","journal-title":"J BUON"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.04.004"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212506"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006308619659"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.009"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1673-3"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00890-5"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489065"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211030210"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101563"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12863"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.7295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:26:59Z","timestamp":1724052419000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.7295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/cam4.7295"],"URL":"https:\/\/doi.org\/10.1002\/cam4.7295","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e7295"}}